Navigation Links
SuperGen's DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine
Date:4/14/2008

Restored sensitivity to cisplatin observed in ovarian carcinoma xenografts

DUBLIN, Calif., April 14 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced as part of a series of presentations at the 2008 AACR Annual Meeting that S-110, its DNA methyltransferase inhibitor, improves in vivo efficacy of decitabine (Abstract No. 2613).

Entitled, "Decitabine administered as a Dinucleotide prodrug increases its in vivo efficacy due to enhanced drug delivery and stability," the poster highlights data indicating that S-110 showed robust anti-tumor activity in prostate and cisplatin-resistant ovarian carcinoma xenograft models. Additionally, S-110 restored sensitivity to cisplatin in the ovarian cancer model. Importantly, reduced toxicity was observed along with an increased half-life compared to decitabine.

"S-110's increased half-life, reduced toxicity and improvement of efficacy when compared to decitabine in its currently marketed formulations make it an attractive, next-generation hypomethylator for the treatment of hematoligic malignancies," said Dr. James Manuso, SuperGen's President and CEO. "As we develop S-110 further, we will continue to explore its potential to enhance solid tumors' sensitivity to standard chemotherapy agents, including cisplatin. We look forward to advancing this promising candidate to clinical trials later this year or early next year."

Copies of the 2008 AACR Annual Meeting poster presentations will be available in the pipeline section of SuperGen's Web site http://www.supergen.com.

About SuperGen

Based in Dublin, Calif., SuperGen Inc. is a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit http://www.supergen.com.

Forward-Looking Statements

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.

Contacts

Timothy L. Enns Mary M. Vegh

SuperGen Inc. SuperGen Inc.

SVP, Corporate Communications & Business Manager, Investor

Development Relations

Tel: (925) 560-0100 Tel: (925) 560-2845

E-mail: tenns@supergen.com E-mail:

mary.vegh@supergen.com


'/>"/>
SOURCE SuperGen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
2. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
3. Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer
4. PTC Therapeutics Presents Encouraging Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer Symposium
5. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
6. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
10. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
11. Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... SAN DIEGO , Jan. 18, 2017 /PRNewswire/ ... manufacturing solutions for cell and advanced therapies , ... the French biopharmaceutical company developing "tumor starvation" treatments ... unmet medical needs. Under the agreement, Invetech will ... products based on Erytech,s proprietary ERYCAPS technology platform, ...
(Date:1/18/2017)... -- After the recent election cycle, it is ... both for medical and recreational purposes are shifting. The evidence ... use of cannabis, but the focus is coming from both ... the North American legal cannabis market posted $6.7 billion in ... research projects sales will grow at a compound annual growth ...
(Date:1/17/2017)... , Jan. 17, 2017 North America Insulin ... new report, "North America Insulin Delivery Market Outlook to ... Insulin Delivery market. The report provides value, in millions ... (USD) within market segments - Insulin Pens, Insulin Pumps, ... report also provides company shares and distribution shares data ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... January 18, 2017 , ... ... their Vice President of Franchise Development, Paula Turner Pizarro, was recently featured on ... which features the insights of top business leaders from across the globe, provides ...
(Date:1/18/2017)... ... January 18, 2017 , ... Catalent Pharma Solutions, ... biologics and consumer health products, today announced that Mr. Michael Merges, Director of ... Conference, to be held at the Mayflower Hotel, Washington DC, on Jan. 24 ...
(Date:1/18/2017)... ... January 18, 2017 , ... Floundering on New Year’s resolutions? Need an excuse ... for a reset. The U.S. Apple Association agrees and recommends starting each day ... that contribute to heart disease. , The U.S. Apple Association – which represents apple ...
(Date:1/17/2017)... Chicago, Illinois (PRWEB) , ... January 17, 2017 , ... ... Antonio Breast Cancer Symposium (SABCS) or those who desire a more intimate review and ... Antonio: Breast Cancer – Bench to Bedside—is being offered by Imedex on February 4, ...
(Date:1/17/2017)... ... January 17, 2017 , ... Etymotic Research will demonstrate ... Music Merchants (NAMM) winter trade show, Booth #2876, at the Anaheim Convention Center ... been the gold standard for high-definition, in-ear earphones. This classic earphone has been ...
Breaking Medicine News(10 mins):